Anandamide, the first identified endogenous cannabinoid and TRPV1 agonist, is one of a
series of endogenous N-acylethanolamines, NAEs. We have generated novel assays to …

Mammalian cells produce both N-arachidonoylethanolamine (20: 4n-6 NAE, anandamide)
and 2-arachidonoylglycerol (2-AG), lipid signaling molecules that activate cannabinoid …

Although it is now generally accepted that long-chain N-acylethanolamines and their
precursors, N-acylethanolamine phospholipids, exist as trace constituents in virtually all …

Endocannabinoids are endogenous ligands of the cannabinoid receptors CB 1 and CB 2.
Two arachidonic acid derivatives, arachidonoylethanolamide (anandamide) and 2 …

Recent reports have suggested that N-arachidonoylethanolamine (anandamide) acts as an
endogenous ligand for cannabinoid receptors in mammalian brain. Here we describe …

Many aspects of the physiology and pharmacology of anandamide (arachidonoyl
ethanolamide), the first endogenous cannabinoid ligand (“endocannabinoid”) isolated from …

Since the discovery of the two cannabinoid receptors, CB 1 and CB 2, several molecules,
commonly defined as endocannabinoids, able to bind to and functionally activate these …

The first evidence that arachidonoylethanolamide, or anandamide, is the endogenous
compound which specifically binds to and activates brain-type cannabinoid receptors was …

The endocannabinoid anandamide (N-arachidonoylethanolamine, AEA), a physiologically
occurring bioactive compound on CB1 and CB2 receptors, has multiple physiological …

Anandamide (N-arachidonoylethanolamine) was the first ligand to be identified as an
endogenous ligand of the G-protein coupled cannabinoid CB1 receptor. Subsequently, two …